Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimer's disease: A systematic review

Iimori, Takashi; Nakajima, Shinichiro; Miyazaki, Takahiro; Tarumi, Ryosuke; Ogyu, Kamiyu; Wada, Masataka; Tsugawa, Sakiko; Masuda, Fumi; Daskalakis, Zafiris J.; Blumberger, Daniel M.; Mimura, Masaru; Noda, Yoshihiro

doi:10.1016/j.pnpbp.2018.06.014

Cited by 68 publications

(38 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, rTMS has been proposed as a new treatment option for cognitive dysfunction, which alters the neuronal activity in the applied area and related areas 6,18 . Most of the literatures showed that rTMS was effective on attention and executive functions in certain patients with depression 19 . But in SCZ, only two studies have reported the promising effect of rTMS on cognitive function as compared with sham control.…”

Section: Discussionmentioning

confidence: 99%

“…However, the recent double-blind, sham-controlled trials of rTMS in patients with SCZ showed that 10 Hz rTMS targeting to the left DLPFC for 3 weeks was not superior to sham rTMS in the improvement of numerous cognitive domains 18 . Moreover, a most recent meta-analysis demonstrated that prefrontal rTMS exerted beneficial effects on attention and executive deficits in certain depressive patients but not in the patients with SCZ 19 . It should be noted that the treatment protocols regarding rTMS efficiency are not consistent.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia

et al. 2020

View full text Add to dashboard Cite

Cognitive impairment is a central aspect of schizophrenia (SCZ) that occurs at the onset of the disease and is related to poor social function and outcome in patients with SCZ. Recent literatures have revealed repetitive transcranial magnetic stimulation (rTMS) to be one of the efficient medical interventions for cognitive impairments. However, no study has been conducted to investigate the treatment effectiveness of 20 Hz rTMS with neuronavigation system administered to the left dorsolateral prefrontal cortex (DLPFC) in patients with schizophrenia. In this randomized, double-blind and sham-controlled study, 56 patients were enrolled in 20 Hz rTMS (n = 28) or sham stimulation (n = 28) over left DLPFC for 8 weeks. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was performed to measure the cognitive function at baseline and after 8 weeks of rTMS treatment. The positive and negative syndrome scales (PANSS) was performed to assess the clinical symptoms at baseline, after 2-week treatment, 4-week treatment, 6-week treatment, and 8-week treatment. Totally, 15 subjects (seven in active group and eight in sham group) dropped out during the trial and the main findings were from completed 41 patients. At 2 weeks, 4 weeks, and 6 weeks, there were no significant differences in PANSS total score and subscores between the sham and treatment groups. At 8 weeks, the 20 Hz rTMS significantly increased the immediate memory score compared with the sham. Furthermore, the improvement in the immediate memory score was correlated with the decrease in the excitement factor score of the patients with SCZ. Our results suggest that 20 Hz rTMS appears to be an effective treatment for improving the cognitive performance and reducing the clinical symptoms of patients with SCZ.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Moreover, two studies reported that stimulation of six functional regions of the brain also revealed a benefit for cognitive function [ 14 , 16 ]. It has been widely known that the prefrontal cortex plays a critical role in cognitive functions [ 25 ], which is abnormally disturbed in AD [ 26 ]. Therefore, the use of rTMS over DLPFC may improves cognition by a direct stimulation of this cortical area and activation of connected circuits in remote structures.…”

Section: Discussionmentioning

confidence: 99%

Repetitive transcranial magnetic stimulation for the treatment of Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials

et al. 2018

View full text Add to dashboard Cite

BackgroundSeveral studies have demonstrated that repetitive transcranial magnetic stimulation (rTMS) may have a beneficial effect in Alzheimer’s disease (AD). Nevertheless, the clinical benefit of rTMS for AD remains inconclusive.ObjectiveThis systematic review and meta-analysis aimed to evaluate the efficacy and safety of rTMS in AD.MethodsWe searched PubMed, Embase and Cochrane for randomized controlled trials (RCTs) of rTMS for AD. We calculated pooled estimates of mean difference (MD) with 95% confidence intervals (CI). The protocol was registered at International Prospective Register of Systematic Reviews (PROSPERO) (number CRD42018089990).ResultsFive RCTs involving 148 participants were included in this review. Compared with sham stimulation, high-frequency rTMS led to a significant improvement in cognition as measured by ADAS-cog (MD = -3.65, 95% CI -5.82 to -1.48, p = 0.001), but not MMSE (MD = 0.49, 95% CI -1.45 to 2.42, p = 0.62). High-frequency rTMS also improved the global impression in comparison to the placebo (MD = -0.79, 95% CI -1.24 to -0.34, p = 0.0006). There was no significant difference in mood (MD = -1.36, 95% CI -3.93 to 1.21, p = 0.30) and functional performance (MD = 0.59, 95% CI -1.21 to 2.38, p = 0.52) between high-frequency rTMS and sham groups. Only one trial included low-frequency rTMS reported no significant improvement in cognition, mood and functional performance. Few mild adverse events were observed in both the rTMS and sham groups.ConclusionsRTMS is relatively well tolerated, with some promise for cognitive improvement and global impression in patients with AD. Our findings also indicate the variability between ADAS-cog and MMSE in evaluating global cognitive impairment.

show abstract

“…Results from a large scale multisite study suggests that treatment with antipsychotic medication only results in limited cognitive improvement (156). In addition to pharmacological treatments, a recent systematic review found that repeated transcranial magnetic stimulation may be beneficial in improving verbal and working memory, but not other functions such as cognitive flexibility (157).…”

Section: Interventions To Improve Cognition In Meth Use Disorder: Insmentioning

confidence: 99%

Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research

et al. 2019

View full text Add to dashboard Cite

Despite the prevalence of methamphetamine (meth) use disorder, research on meth is disproportionately scarce compared to research on other illicit drugs. Existing evidence highlights cognitive deficits as an impediment against daily function and treatment of chronic meth use. Similar deficits are also observed in schizophrenia, and this review therefore draws on schizophrenia research by examining similarities and differences between the two disorders on cognition and related neural findings. While meth use disorder and schizophrenia are two distinct disorders, they are highly co-morbid and share impairments in similar cognitive domains and altered brain structure/function. This narrative review specifically identifies overlapping features such as deficits in learning and memory, social cognition, working memory and inhibitory/impulse control. We report that while working memory deficits are a core feature of schizophrenia, such deficits are inconsistently observed following chronic meth use. Similar structural and functional abnormalities are also observed in cortical and limbic regions between the two disorders, except for cingulate activity where differences are observed. There is growing evidence that targeting cognitive symptoms may improve functional outcome in schizophrenia, with evidence of normalized abnormal brain activity in regions associated with cognition. Considering the overlap between meth use disorder and schizophrenia, targeting cognitive symptoms in people with meth use disorder may also improve treatment outcome and daily function.

show abstract

Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimer's disease: A systematic review

Cited by 68 publications

References 78 publications

High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia

High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia

Repetitive transcranial magnetic stimulation for the treatment of Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials

Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research

Contact Info

Product

Resources

About